Home
PB Ratio of Corona Remedies Ltd
Corona Remedies Ltd
NSE: CORONA
PB Ratio
Key Highlights
- The latest PB Ratio of Corona Remedies Ltd is 14.4.
- The PB ratio of the Corona Remedies Ltd is above 3 which indicates that the stock is overvalued but this is common in high-growing sectors.
- The P/B Ratio of Corona Remedies Ltd changed from 0 on March 2023 to 0 on March 2025 . This represents a CAGR of 0.0% over 3 years.
Historical P/B Ratio of Corona Remedies Ltd
The price-to-book (P/B) ratio compares a company's market capitalization to its book value by dividing its stock price per share by its book value per share. How to calculate Price-to-Book (P/B) Ratio? The Price-to-Book Ratio is used to determine the relationship between the total value of a company's outstanding shares and the net value of its assets. Before calculating the P/B ratio, investors need to overlook the market capitalization of a company. Market capitalization = market value of a stock X no. of outstanding shares Now, you need to know the net value of an organization's assets. Book Value of Assets = Total Assets - Total Liabilities of a company After knowing the value of the above ratios, here is the formula for the P/B Ratio: P/B Ratio = Market Capitalization/ Book Value of Assets or you can also use this formula P/B ratio = Market Price Per Share/ Book Value of Asset Per Share
Historical P/B Ratio of Corona Remedies Ltd
Company Fundamentals for null
Market Cap
8,718 Cr
EPS
24.5
P/E Ratio (TTM)
58.1
P/B Ratio (TTM)
14.4
Day’s High
1462.3
Day’s Low
1413.7
DTE
0.1
ROE
41.5
52 Week High
1523.95
52 Week Low
1336.95
ROCE
51.9
Market Price of Corona Remedies Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
| Date | |
|---|---|
| 09 Jan 2026 | 1425.6 |
| 08 Jan 2026 | 1463.85 |
| 07 Jan 2026 | 1446.9 |
| 06 Jan 2026 | 1430.35 |
| 05 Jan 2026 | 1466.5 |
| 02 Jan 2026 | 1445.7 |
| 01 Jan 2026 | 1402.95 |
| 31 Dec 2025 | 1385.85 |
| 30 Dec 2025 | 1384.25 |
| 29 Dec 2025 | 1365.75 |
SWOT Analysis Of Corona Remedies Ltd
BlinkX Score for Corona Remedies Ltd
Asset Value vs Market Value of Corona Remedies Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/B Ratio
| Company | PB | Market Cap |
|---|
| Corona Remedies Ltd | 14.38 | 8718 |
| Sun Pharmaceutical Industries Ltd | 99.2 | 415073 |
| Divis Laboratories Ltd | 578.3 | 175657 |
| Torrent Pharmaceuticals Ltd | 249.8 | 134121 |
| Cipla Ltd | 411.6 | 118431 |
| Company | |
|---|---|
| Corona Remedies Ltd | 14.38 |
| Sun Pharmaceutical Industries Ltd | 99.2 |
| Divis Laboratories Ltd | 578.3 |
| Torrent Pharmaceuticals Ltd | 249.8 |
| Cipla Ltd | 411.6 |
PB Ratio of Corona Remedies Ltd Explained
₹8718
Market cap
₹99
Book Value per Share
14.4X
PB Ratio
Historical Market Cap of Corona Remedies Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Corona Remedies Ltd
Market Cap
Historical Revenue, EBITDA and Net Profit of Corona Remedies Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Corona Remedies Ltd
Revenue
EBITDA
Net Profit
Dividend Payout Over Time
Corona Remedies Ltd News Hub
Shares of Corona Remedies list in B group
The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and
Read more
15 Dec 25
Corona Remedies Q2 PAT climbs 22% YoY to Rs 52 cr
Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B
Read more
03 Jan 26
Corona Remedies gains as Q2 PAT climbs 22% YoY to Rs 52 cr
Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B
Read more
05 Jan 26
Corona Remedies spurts on market debut
The stock was listed at Rs 1,452, exhibiting a premium of 36.72% to the issue price. So far, the sto
Read more
15 Dec 25
